Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups-Reference-Cited by-同舟云学术

Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups

Published:2023-10 Issue: Volume: Page:
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wong N.Z.H.,Yap D.W.T.,Ong R.J.M.,Zhao J.J.,Chan Y.H.,Tey J.C.S.,Sundar R.,Lim J.S.J.,Dawood S.S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference44 articles.

1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study;Martín;Eur J Cancer. Jun,2022

2. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer;Slamon;New England Journal of Medicine,2019

3. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer;Hortobagyi;New England Journal of Medicine,2022

4. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study;Im;J Glob Oncol,2019

5. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer;Johnston;npj Breast Cancer,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wise and skillful utilization of contemporary endocrine therapies for the treatment of ER+/HER2– advanced breast cancer;Oncology in Clinical Practice;2024-08-21

2. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer;Cancer Treatment Reviews;2024-02